The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Major Genes ¹

Cited Antoniou et al. as reference 87 ².

Added text ² about a large population-based family study that found that the risk of breast cancer for relatives of probands with deleterious BRCA1/2 mutations expressed significant variation due to unknown factors (cited Begg et al. as reference 88).

Cited Evans et al and Tonin et al. as references 184 and 185 ³, respectively.

Interventions ⁴

Added levels of evidence throughout this section.

Revised text ⁵ to state that proliferative lesions associated with an increased risk of breast cancer were noted in 37% to 46% of women with mutations undergoing either unilateral or bilateral risk-reducing mastectomy (cited Kroiss et al. as reference 82).

Added text ⁵ about a Swedish study of 100 women with a hereditary risk of breast cancer, 50 of whom were BRCA1 or BRCA2 mutation carriers (cited Isern et al. as reference 84).

Revised text ⁶ to state that a biomarker with a PPV of 10% implies that ten surgical procedures would be required to identify one case of ovarian cancer; the remaining nine surgeries would represent false-positive test findings.

Added text ⁷ to state that an assay was available commercially under the trade name OvaSure™ until its voluntary withdrawal from the market by the manufacturer (cited Response to FDA Warning Letter).

Added text ⁸ to state that based on a a recently published correction, investigators have retracted their claim that a biomarker test is suitable for population screening.

Psychosocial Issues in Inherited Breast Cancer Syndromes ⁹

Expanded text ¹⁰ about studies that have examined uptake and adherence to cancer risk management options.

Revised text ¹¹ layout in Tables 6 and 7.